SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
VCEL

Vericel Corp (NASDAQ:VCEL)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$57.52-$0.74 (-1.27%)
 
Market cap
$2.94B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 4, 1997
Website
Market Cap$2.94B+45.3%
Revenue (ttm)$324.17M+25.3%
Net Income$33.31M+154.6%
EPS$0.64+170.3%
Shares Out51.03M
PE Ratio87.15
Forward PE60.86
Dividendn/a
Ex-Dividend Daten/a
Volume582,315
Open$58.11
Previous Close$58.26
Day's Range$57.39 - $59.49
52-Week Range$28.95 - $59.75
Beta1.06
AnalystsBuy
Price Target$62.50(+8.66%)
Earnings DateFeb 25, 2027

About VCEL

Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.

Address
25 Blue Sky Drive, Burlington, MA, 01803, US
Market Cap
2.94 billion
Employees
398
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$5.70M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $57.00 (-2.2%)

3 firms rating VCEL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From VCEL’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-1.27%
5 Days
+1.18%
1 Month
+40.50%
6 Months
+63.64%
1 Year
+45.33%

$VCEL stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in VCEL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by VCEL's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

VCEL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

VCEL Revenue by Segment

$88.37MTotal
Product sales, net$85.37M96.61%
Nexobrid$3.00M3.39%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New VCEL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to VCEL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in VCEL

IJRiShares Core S&P Small-Cap ETF$179.68M
IWMiShares Russell 2000 ETF$78.72M
XBIState Street SPDR S&P Biotech ETF$65.90M
VTIVanguard Morningstar Total Stock Market ETF$51.84M
IWOiShares Russell 2000 Growth ETF$28.42M
SPSMState Street SPDR Portfolio S&P 600 Small Cap ETF$27.36M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from VCEL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
95
News & Sentiment
20% of score
72

News check: Analyst upgrade to $65 PT, rising earnings estimates, and Q3 earnings call signal positive momentum for VCEL.

Recent Insider Activity

Buys
0
Sells
14
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-39.0 since Aug 21
0255075100Aug 21 — Insider Score 39.0Aug 22 — Insider Score 39.0Aug 23 — Insider Score 39.0Aug 24 — Insider Score 39.0Aug 25 — Insider Score 39.0Aug 26 — Insider Score 39.0Aug 27 — Insider Score 39.0Aug 28 — Insider Score 39.0Aug 29 — Insider Score 39.0Aug 30 — Insider Score 39.0Aug 31 — Insider Score 39.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PBEInvesco Biotechnology & Genome ETF3.69%
FFTYCapForce IBD 50 ETF2.05%
SBIOALPS Medical Breakthroughs ETF1.92%
PSCHInvesco S&P SmallCap Health Care ETF1.60%
LFSCF/M Emerald Life Sciences Innovation ETF1.46%
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF1.37%
JSMLJanus Henderson Small Cap Growth Alpha ETF1.22%
CAFGPacer US Small Cap Cash Cows Growth Leaders ETF1.12%
LITLSimplify Piper Sandler US Small-Cap PLUS Income ETF0.78%
XBIState Street SPDR S&P Biotech ETF0.64%
AESGHarbor AlphaEdge Small Cap Growth ETF0.60%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.54%

Weight is the stock’s share of each fund’s holdings.